Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia by , Springer Japan
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9784431557142
Publisher: Springer Japan Publication: November 5, 2015
Imprint: Springer Language: English
Author:
ISBN: 9784431557142
Publisher: Springer Japan
Publication: November 5, 2015
Imprint: Springer
Language: English

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

More books from Springer Japan

Cover of the book Fundamentals of Semiconductor Lasers by
Cover of the book DNA Replication, Recombination, and Repair by
Cover of the book Studies on Porous Monolithic Materials Prepared via Sol–Gel Processes by
Cover of the book Environmental Systems Studies by
Cover of the book Evolution and Diversification of Land Plants by
Cover of the book Shock-Cloud Interaction in RX J1713.7−3946 by
Cover of the book Nature Technology by
Cover of the book Bioelectrics by
Cover of the book The Prefrontal Cortex as an Executive, Emotional, and Social Brain by
Cover of the book Helicobacter pylori by
Cover of the book Agent-Based Approaches in Economic and Social Complex Systems VII by
Cover of the book HCV/Oxidative Stress and Liver Disease by
Cover of the book Schumann Resonance for Tyros by
Cover of the book Essential Hypertension by
Cover of the book Dementia with Lewy Bodies by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy